Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.76
EPS est.
$0.72
EPS surprise
+5.85%
1-day move
+4.02%
Phibro Animal Health Corporation reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 4.02%. However, the company did not provide revenue figures or any forward guidance, leaving some uncertainty about future performance. Investors may be encouraged by the EPS beat, but the lack of revenue data could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.76 | $0.71 | +5.85% |
| Revenue | N/A | $367M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for animal health. The company develops and markets products for livestock and companion animals, which is crucial as global demand for animal protein continues to rise.
Last quarter
In Q2-2026, Phibro reported an EPS of $0.87, significantly exceeding the estimate of $0.69, marking a 27% surprise. However, the stock fell 0.75% the following day, indicating market caution despite the strong earnings.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+23.55%
Avg 1-day reaction
+0.57%
Analysts expect Phibro to continue its positive earnings trend with an EPS of $0.71 and revenue of $367M. There is cautious optimism given the company's recent performance.
Bull case
If Phibro beats expectations again, it could signal strong operational efficiency and continued demand for its products, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet earnings expectations, it could raise concerns about market demand and operational challenges, leading to a negative reaction.
Key metrics to watch
EPS
$0.71Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$367MRevenue figures will indicate the overall sales performance and market demand for Phibro's products.
The print will turn on these.
Q1
Will Phibro's revenue meet or exceed the consensus estimate of $367M?
Revenue performance is critical to gauge the company's market position and demand for its products.
Q2
How will management address the recent stock price declines despite positive earnings surprises?
Investor sentiment may hinge on management's commentary about future growth and market challenges.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate the potential for Phibro to exceed revenue expectations due to strong demand in the animal health market, which could be bolstered by recent industry trends.
Supporting evidence
Phibro has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.
The options market is pricing in a larger move than historical averages, indicating heightened investor expectations.
Insider selling could indicate a strategic shift rather than a lack of confidence in the company's future.
Key risk
If revenue comes in below $357M, it could undermine the bullish sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The market is debating whether Phibro can sustain its recent earnings momentum amid potential market pressures.
Bull confirmed if
An EPS of $0.73 or higher would confirm strong operational performance and support the bull case.
Bear confirmed if
An EPS below $0.70 would raise concerns about demand and operational efficiency.
What the market is pricing for the move.
Implied Move
±17.72%
Historical Avg
±1.7%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±16.5% while PAHC has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
1.1%
30d HV
46.5%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
103.94%
of float
Insider
0.88%
of float
Holders
308
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,219,040 sh · $121.4M
15.25%
-1.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Phibro beats estimates, history suggests the stock could rise by around 0.17%, confirming strong operational efficiency.
In line / cautious
An in-line report could lead to a muted reaction as investors await clearer guidance from management.
Miss
If the company misses expectations, history suggests a potential decline of around 1.56%, raising concerns about future performance.
The lines on the call that would change the story.
FMR, LLC
3,160,281 sh · $119.2M
14.97%
45.4%
State Street Corporation
1,038,382 sh · $39.2M
4.92%
9.3%
Millennium Management Llc
936,701 sh · $35.3M
4.44%
1578.1%
Vanguard Capital Management LLC
923,318 sh · $34.8M
4.37%
3.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.